The stock of Talis Biomedical Corporation (NASDAQ: TLIS) has increased by 14.30 when compared to last closing price of 0.47.Despite this, the company has seen a gain of 17.82% in its stock price over the last five trading days.
Is It Worth Investing in Talis Biomedical Corporation (NASDAQ: TLIS) Right Now?
Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 2 as “sell.”
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The average price suggested by analysts for TLIS is $0.35, The public float for TLIS is 24.03M, and currently, shorts hold a 1.38% of that float. The average trading volume for TLIS on May 25, 2023 was 86.97K shares.
TLIS’s Market Performance
TLIS’s stock has seen a 17.82% increase for the week, with a 7.36% rise in the past month and a -6.87% fall in the past quarter. The volatility ratio for the week is 7.77%, and the volatility levels for the past 30 days are at 7.82% for Talis Biomedical Corporation The simple moving average for the past 20 days is 9.33% for TLIS’s stock, with a -12.76% simple moving average for the past 200 days.
TLIS Trading at 8.44% from the 50-Day Moving Average
After a stumble in the market that brought TLIS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.38% of loss for the given period.
Volatility was left at 7.82%, however, over the last 30 days, the volatility rate increased by 7.77%, as shares surge +8.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.84% lower at present.
During the last 5 trading sessions, TLIS rose by +17.82%, which changed the moving average for the period of 200-days by -30.09% in comparison to the 20-day moving average, which settled at $0.4919. In addition, Talis Biomedical Corporation saw 20.15% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for TLIS
Current profitability levels for the company are sitting at:
- -3086.14 for the present operating margin
- -447.43 for the gross margin
The net margin for Talis Biomedical Corporation stands at -3094.52. Equity return is now at value -69.70, with -56.30 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 10.52.
Conclusion
In conclusion, Talis Biomedical Corporation (TLIS) has had a mixed performance lately. Opinion on the stock among analysts is bearish, with some giving it a “sell” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
